AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

NZ sharemarket closes lower, tech stocks buoyed by Oracle update
Markets Market Close

NZ sharemarket closes lower, tech stocks buoyed by Oracle update

The S&P/NZX 50 Index closed down 0.35% or 47.09 points.

Tom Raynel 11 Sep 2025
Average home insurance tops $2,000
Infrastructure Risky Business

Average home insurance tops $2,000

Insurance premiums in New Zealand have increased dramatically in recent years.

Michael Neilson 11 Sep 2025
How RFK Jnr's Medicare reform could aid this NZ firm
Markets

How RFK Jnr's Medicare reform could aid this NZ firm

'Wild west' conditions hampered its US push. They could be changing.